POINT-Logo-Colour (blue).png
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
September 16, 2022 16:30 ET | POINT Biopharma
INDIANAPOLIS, Sept. 16, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma Prices Public Offering of Common Stock
September 13, 2022 21:47 ET | POINT Biopharma
INDIANAPOLIS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT-Logo-Colour (blue).png
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
September 10, 2022 03:05 ET | POINT Biopharma
Newly published poster on the single-arm 27-patient safety and dosimetry lead-in provides key updates including: A median rPFS time of 11.5 months A best radiographic objective response (CR, PR)...
22157.jpg
Global Nuclear Medicine Market Report 2022: Improved Advancements in Nuclear Imaging Techniques Presents Opportunities
September 06, 2022 07:48 ET | Research and Markets
Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market- Global Industry Size, Share, Trends, Ciompetition, Opportunity and Forecast, 2017-2027 Segmented By Type, By Application, By...
POINT-Logo-Colour (blue).png
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
September 04, 2022 18:10 ET | POINT Biopharma
INDIANAPOLIS, Sept. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
Global Prostate Cancer Nuclear Medicine Diagnostics Market Report 2022-2028 - Increasing Research Activities for Development of Innovative Imaging Agents
August 31, 2022 06:28 ET | Research and Markets
Dublin, Aug. 31, 2022 (GLOBE NEWSWIRE) -- The "Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, PET Product, and End User" report...
Radiopharmaceuticals Global Market Report 2022: Industry Focus Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
August 23, 2022 06:13 ET | Research and Markets
Dublin, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The "Radiopharmaceuticals - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...
POINT-Logo-Colour (blue).png
POINT Biopharma to Publish Abstract at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
August 18, 2022 16:30 ET | POINT Biopharma
In advance of the abstract publication, POINT hosted an educational webinar entitled “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm” Watch the replay at...
Global Radiotherapy Market Report 2022: Growing Use of Particle Therapy for Cancer Treatment & Awareness Initiatives on the Benefits of Radiotherapy Driving Growth
August 18, 2022 05:53 ET | Research and Markets
Dublin, Aug. 18, 2022 (GLOBE NEWSWIRE) -- The "Radiotherapy Market by Type (Product, Service), Technology (LINAC, Stereotactic LINAC, Particle Therapy, Cobalt-60 Teletherapy), Procedure (IMRT, IGRT,...
LOGO.jpg
QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 16, 2022 08:00 ET | QSAM Biosciences Inc.
Progress Shown in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- QSAM...